Epic Sciences

In the News

06.06.2018

AR-V7+ CTCs Predicted Worse PFS, OS in mCRPC

San Diego, Cancer Network — Detection of circulating tumor cells (CTCs) positive for the nuclear-specific AR-V7 protein was an independent predictor of shortened progression-free survival (PFS) and overall survival (OS) when treating metastatic castration-resistant prostate cancer (mCRPC) with abiraterone or enzalutamide, according to results of the PROPHECY study (abstract 5004). The findings were presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1–5 in Chicago.

06.05.2018

Tests identify who would benefit from advanced prostate cancer therapies

San Diego, MedicalXpress – Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led by Duke Cancer Institute. The blood tests, dubbed "liquid biopsies", detect androgen receptor splice variant-7 (AR-V7) circulating in prostate tumor cells. The presence of this variant indicates a poor response to new androgen receptor drugs that are used to treat recurrent, metastatic prostate cancer.

12.06.2017

An Epic Quest to Detect Cancer

San Diego, San Diego Union-Tribune – Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.

08.14.2017

Video - Prostate Cancer: Epic Sciences AR-V7 Test

San Diego, OncLive — Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center

04.28.2017

Biopharma just can’t get enough of Epic Sciences

San Diego, MedCity News — Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.

04.13.2017

Liquid Biopsy Market Sees Continuing Growth of New Technologies, Methods

New York, GenomeWeb – As liquid biopsy products make further inroads in the clinic and in clinical research, rather than coalescing around a few dominant technologies or platforms, investigators and entrepreneurs are continuing to explore and advance a wide range of methods for examining genomic and other molecular biomarkers non-invasively.

07.07.2016

Genomic Health to Market Epic Sciences' AR-V7 Liquid Biopsy Test

New York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.